the most important thing when you take this medication is the dose mg.
AMPYRA® Two-Year Safety Data Presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Two-year data from more than 62,400 people with multiple sclerosis highlight AMPYRA safety profile
ARDSLEY, N.Y.--(BUSINESS WIRE)--Oct. 10, 2012-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced safety data from more than 62,400 people with multiple sclerosis (MS) taking AMPYRA (dalfampridine) Extended Release Tablets, 10 mg during the first two years of availability in the United States. The data showed that the safety profile of AMPYRA is similar to that observed in clinical trials.
This analysis was presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Lyon, France from October 10-13. AMPYRA is known as prolonged-, modified, or sustained-release fampridine (FAMPYRA®) in some countries outside the United States.